temozolomide has been researched along with Dysmyelopoietic Syndromes in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Small recurrences confined to left supraclavicular nodes were treated with surgery alone at 4." | 5.35 | Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide. ( Cheung, NK; Kramer, K; Kushner, BH; Laquaglia, MP; Modak, S, 2008) |
| " We report a 44-year-old woman with t-MDS (refractory anemia with excess blasts) following treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ)." | 4.82 | Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. ( Chang, MC; Chiang, MF; Hsieh, RK; Su, YW, 2005) |
| "Seven patients (4 men; 3 women) ages 34-69 years (median 44), with gliomas (3 Grade 2; 4 Grade 3) were treated with surgery, all but one with involved-field radiotherapy and all with alkylator-based chemotherapy (temozolomide; 6 patients, nitrosoureas; 5 patients, both agents; 5 patients)." | 3.75 | Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia. ( Chamberlain, MC; Raizer, J, 2009) |
| " Commenced 15 years ago, PRRT is now becoming established as first- and second-line therapy for gastroentero pancreatic neuroendocrine tumors (GEPNETs), and early treatment minimizes myelotoxicity, which is the most significant potential adverse event following PRRT." | 2.53 | Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience. ( Kesavan, M; Turner, JH, 2016) |
| " Alternative dosing regimens, such as 1-week on/1-week off, or 3-week on/1-week off, that deliver more prolonged exposure have been observed to result in higher cumulative doses than the standard 5-day regimen and may deplete tumor-derived O6-methylguanine-DNA methyltransferase (MGMT) in tumor cells, thus sensitizing tumor cells to the effects of TMZ." | 2.45 | [Treatment of glioma with temozolomide]. ( Nishikawa, R, 2009) |
| "Small recurrences confined to left supraclavicular nodes were treated with surgery alone at 4." | 1.35 | Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide. ( Cheung, NK; Kramer, K; Kushner, BH; Laquaglia, MP; Modak, S, 2008) |
| "Temozolomide is an effective alkylating agent that is increasingly used for the treatment of pediatric brain tumors." | 1.35 | Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report. ( Auger, N; Bhangoo, R; Da Costa, L; Dufour, C; Grill, J; Jullien, M, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brandwein, JM | 1 |
| Kassis, J | 1 |
| Leber, B | 1 |
| Hogge, D | 1 |
| Howson-Jan, K | 1 |
| Minden, MD | 1 |
| Galarneau, A | 1 |
| Pouliot, JF | 1 |
| Rashidi, A | 1 |
| Sorscher, SM | 1 |
| Kesavan, M | 1 |
| Turner, JH | 1 |
| Kushner, BH | 1 |
| Laquaglia, MP | 1 |
| Kramer, K | 1 |
| Modak, S | 1 |
| Cheung, NK | 1 |
| Dufour, C | 1 |
| Da Costa, L | 1 |
| Auger, N | 1 |
| Jullien, M | 1 |
| Bhangoo, R | 1 |
| Grill, J | 1 |
| Chamberlain, MC | 1 |
| Raizer, J | 1 |
| Nishikawa, R | 1 |
| Kim, SJ | 1 |
| Park, TS | 1 |
| Lee, ST | 1 |
| Song, J | 1 |
| Suh, B | 1 |
| Kim, SH | 1 |
| Jang, SJ | 1 |
| Lee, CH | 1 |
| Choi, JR | 1 |
| Seiter, K | 1 |
| Liu, D | 1 |
| Siddiqui, AD | 1 |
| Lerner, R | 1 |
| Nelson, J | 1 |
| Ahmed, T | 1 |
| Su, YW | 1 |
| Chang, MC | 1 |
| Chiang, MF | 1 |
| Hsieh, RK | 1 |
| Noronha, V | 1 |
| Berliner, N | 1 |
| Ballen, KK | 1 |
| Lacy, J | 1 |
| Kracher, J | 1 |
| Baehring, J | 1 |
| Henson, JW | 1 |
4 reviews available for temozolomide and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
Topics: Capecitabine; Dacarbazine; Female; Humans; Lutetium; Male; Middle Aged; Myelodysplastic Syndromes; N | 2016 |
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2009 |
Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.
Topics: Acute Disease; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosomes, | 2005 |
Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature.
Topics: Aged; Breast Neoplasms; Dacarbazine; Female; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndr | 2006 |
2 trials available for temozolomide and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Survi | 2014 |
Evaluation of temozolomide in patients with myelodysplastic syndrome.
Topics: Aged; Anemia; Antineoplastic Agents, Alkylating; Cardiomyopathies; Dacarbazine; Drug Evaluation; Fem | 2004 |
5 other studies available for temozolomide and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Humans; Male; Middle Aged; Myelodysplastic Syndromes | 2015 |
Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide.
Topics: Adolescent; Adult; Cell Transformation, Neoplastic; Child; Combined Modality Therapy; Dacarbazine; F | 2008 |
Treatment-related myelodysplastic syndrome after temozolomide use in a child: first report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Combined Modality Therapy; Cranial Irradi | 2008 |
Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Follow-Up Stud | 2009 |
Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.
Topics: Adult; Aged; Biopsy; Bone Marrow Cells; Brain Neoplasms; Dacarbazine; Disease Progression; Female; G | 2009 |